SEARCH
= Paid-up subscribersPractitioner 2011; 255 (1739): 10
5-α reductase inhibitors may delay the progression of low-grade prostate cancer
20 Apr 2011
Giving 5-alpha reductase inhibitors (5-ARIs) to men with low-risk prostate cancer undergoing active surveillance was associated with a lower rate of pathologic progression in a small retrospective cohort study. Men on 5-ARIs also had a longer median time to disease progression and were less likely to abandon active surveillance for active treatment. 'This study has limitations, in terms of a retrospective design with small numbers, but it paves the way for the REDEEM study, a large randomised controlled trial on the use of dutasteride in this setting.'
This article can only be accessed if you are a registered user of thepractitioner.co.uk or a subscriber to The Practitioner.